Suggested remit: To appraise the clinical and cost effectiveness of vutrisiran within its marketing authorisation for treating transthyretin amyloidosis with cardiomyopathy
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6470

Provisional Schedule

Committee meeting 08 July 2025
Expected publication 12 November 2025

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors Alnylam Pharmaceuticals
Others Department of Health and Social Care
  NHS England
Patient carer groups Amyloidosis UK
  Cardiomyopathy UK
  Gene People
Professional groups British Cardiovascular Society
  Royal College of Physicians
Associated public health groups None
Comparator companies Pfizer (tafamidis) – confidentiality agreement returned, participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  NHS Wales Joint Commissioning Committee
  Scottish Medicines Consortium
  Welsh Government
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
12 December 2024 Referral
25 November 2024 Invitation to participate
04 October 2024 - 01 November 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6470
04 October 2024 In progress. Scoping commencing
15 July 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
15 July 2024 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual